News
2020-09-27
New product launch- QDx Malaria PAN/Pf
Early and accurate diagnosis of malaria is necessary in improving the effectiveness of Malaria management.
DiaSys Diagnostics India Pvt. Ltd introduces a new, high sensitive “QDx Malaria PAN/Pf”- an antigen detection kit based on Immuno-chromatography assay for the qualitative detection and differentiation of P. falciparum from other Plasmodium species in human blood as an aid in the diagnosis of Malaria.
The kit has a capability of detecting low parasitic count so as to meet the WHO requirement. It provides ease of interpretation with two color band to differentiate control and test band during the screening of patient samples within time range of 5-20 minutes.
2020-09-27
New product launch- QDx Malaria PAN/Pf
Early and accurate diagnosis of malaria is necessary in improving the effectiveness of Malaria management.
DiaSys Diagnostics India Pvt. Ltd introduces a new, high sensitive “QDx Malaria PAN/Pf”- an antigen detection kit based on Immuno-chromatography assay for the qualitative detection and differentiation of P. falciparum from other Plasmodium species in human blood as an aid in the diagnosis of Malaria.
The kit has a capability of detecting low parasitic count so as to meet the WHO requirement. It provides ease of interpretation with two color band to differentiate control and test band during the screening of patient samples within time range of 5-20 minutes.
2020-09-27
New product launch- QDx Dengue NS1
NS1 Detection: For early diagnosis of DV
QDx Dengue NS1 Ag test is a serum based test on the principle of lateral flow Immuno-chromatography to detect the non-structural protein NS1 of Dengue Virus from Human blood during the acute phase (0-7 Days) of the infection. The test uses synthetically labeled antibodies to detect the NS1 protein.
Early clinical findings recognizing early signs of shock and initiating intensive supportive therapy can reduce risk of death among patients with severe dengue to <0.5%.
2020-04-26
Proud moment for DiaSys India to receive Certification for Medical Devices (ICMED) 13485
DiaSys India has been awarded the certificate of ICMED 13485; Certificate Registration Number 9940000025, on 8th April 2020, for its Mahape, Navi Mumbai facility.
The audit was carried out by TUV SUD South Asia- the first certification body in India to be accredited by NABCB for certifying Medical Devices Organization under ISO 13485 and ICMED Scheme.
TUV SUD South Asia awarded this certificate to DiaSys India under the scope of “Manufacturing & Distribution of In-Vitro Diagnostic Products (Biochemistry & Hematology Reagents, Rapid Test Strips and Analyzers).
DiaSys India is one among the only five IVD companies in India today to be certified for the ICMED 13485.
2020-04-02
"QDx InstaLyte" awarded as the “Most Innovative Product of the Year” at the 10th MT India Healthcare Awards 2020 hosted by Medical Fair 2020 in Mumbai.
QDx InstaLyte- World’s First Truly Modular Electrolyte Analyzer gets awarded as the “Most Innovative Product of the Year” at the 10th MT India Healthcare Awards 2020 hosted by Medical Fair 2020 in Mumbai. It is one of the biggest platform in India where innovative products across IVD industry are screened through multiple rounds and the winner is awarded as “Most Innovative Product”. MT India Healthcare Awards is a completely unbiased platform where results are decided solely on the basis of the merits, the product possesses. The award ceremony took place on 6th March 2020 at NESCO, Mumbai in the presence of Key opinion leaders across In-vitro diagnostics Segment. A proud moment for the entire DiaSys Group as DiaSys India receives this prestigious award for the year 2020.
2020-04-02
DiaSys India has been awarded the EN ISO13485:2016 QMS certificate for its Mahape, Navi Mumbai facility
DiaSys India has been awarded the EN ISO13485:2016 QMS certificate on 10th February 2020, for its Mahape, Navi Mumbai facility. The audit was extensively carried out by TUV SUD South Asia under the scope of “Manufacturing & Distribution of In-Vitro Diagnostic Products (Biochemistry & Hematology Reagents, Rapid Test Strips) and Analyzers”. DiaSys India will also soon be among the only five IVD companies in India today who have certified for the ICMED 13485, the Indian Certification for Medical Devices (ICMED) -Quality Management systems for regulatory purposes. TUV SUD South Asia was the certification body for this too. The ICMED 13485 certificate scheme was developed by the Government of India, its accredited certification bodies and the Indian Medical Device Industry represented by the Quality Council of India (QCI), the National Accreditation Board for Certification Bodies (NABCB) and Association of Indian Medical Device Industry (AIMED) respectively. This certification is based on the ISO 13485 - Medical devices – Quality management systems and is aimed to encourage Indian companies to manufacture quality medical devices and enhancing credibility and competitiveness. This certification will help our company in reaching out wider in the Indian market, and scale up our operations as it further enhances confidence among buyers.
2020-03-05
Medical Fair 2020
DiaSys Diagnostics India Private Limited invites you to Medical Fair India 2020 being held at Bombay Convention and Exhibition Center, Mumbai from 5-7th March 2020.
#DiaSysIndia
#MedicalFair2020
#DiagnosisBeforeTherapy
2020-01-22
AIICME 2020, 31st Jan - 2nd Feb, Ahmedabad
Celebrating 25th AIPNA-ICP CME anniversary. AIPNA have taken initiative along with ICP to share the knowledge, update recent trends and educate the Indian Pathologists Fraternity.
2020-01-22
MEDLAB MIDDLE EAST 2020
MEDLAB MIDDLE EAST 2020, the world`s largest and most important trade fair for laboratory and diagnostics in the MENA region starts on 03 February.
2019-12-03
Diabetes and HbA1c testing
Diabetes, a chronic lifelong metabolic condition wherein, the body becomes resistant to the effect of insulin or does not produce enough Insulin to process glucose. Characterized by elevated blood glucose levels, Diabetes for a long period leads to serious cardiovascular disorders, neuropathy, Glaucoma and renal failure.